ES2193615T3 - .nhibidor de la angiogenesis. - Google Patents

.nhibidor de la angiogenesis.

Info

Publication number
ES2193615T3
ES2193615T3 ES99106760T ES99106760T ES2193615T3 ES 2193615 T3 ES2193615 T3 ES 2193615T3 ES 99106760 T ES99106760 T ES 99106760T ES 99106760 T ES99106760 T ES 99106760T ES 2193615 T3 ES2193615 T3 ES 2193615T3
Authority
ES
Spain
Prior art keywords
angiogenesis
formula
compounds
cysteine protease
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99106760T
Other languages
English (en)
Spanish (es)
Inventor
Chiho Fukiage
Mitsuyoshi Azuma
Jun Inoue
Masayuki Nakamura
Yuka Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2193615T3 publication Critical patent/ES2193615T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES99106760T 1995-10-25 1996-10-23 .nhibidor de la angiogenesis. Expired - Lifetime ES2193615T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP27748595 1995-10-25
JP24804696 1996-09-19

Publications (1)

Publication Number Publication Date
ES2193615T3 true ES2193615T3 (es) 2003-11-01

Family

ID=26538555

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99106760T Expired - Lifetime ES2193615T3 (es) 1995-10-25 1996-10-23 .nhibidor de la angiogenesis.
ES99102501T Expired - Lifetime ES2190139T3 (es) 1995-10-25 1996-10-23 Inhibidor de la angiogenesis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99102501T Expired - Lifetime ES2190139T3 (es) 1995-10-25 1996-10-23 Inhibidor de la angiogenesis.

Country Status (13)

Country Link
US (2) US6057290A (no)
EP (2) EP0927716B1 (no)
AR (1) AR004694A1 (no)
AT (3) ATE230275T1 (no)
AU (1) AU716495B2 (no)
BR (1) BR9605267A (no)
CA (1) CA2188817C (no)
DE (3) DE69628050T2 (no)
ES (2) ES2193615T3 (no)
HU (1) HUP9602943A3 (no)
MX (1) MX9605156A (no)
NO (1) NO964514L (no)
PL (1) PL316669A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226740A1 (en) * 1995-07-13 1997-01-30 Mitsuyoshi Azuma Piperazine derivative and its uses
US6214800B1 (en) * 1995-10-25 2001-04-10 Senju Pharmaceutical Co., Ltd. Angiogenesis inhibitor
DE19718826A1 (de) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
PT1022276E (pt) * 1997-09-04 2003-10-31 Nippon Chemiphar Co Derivados de epoxissuccinamida
US6015787A (en) * 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
DE69925578T2 (de) 1998-03-05 2006-04-27 Senju Pharmaceutical Co., Ltd. Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
AU2852699A (en) * 1998-03-20 1999-10-18 Senju Pharmaceutical Co., Ltd. Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment
GB9819860D0 (en) * 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
CZ20012320A3 (cs) 1998-12-23 2002-10-16 G. D. Searle & Co. Léčivo s obsahem inhibitoru cyklooxygenázy-2 a jednoho nebo více antineoplastických činidel pro kombinační terapii při léčení neoplasie
AU3196300A (en) * 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
KR20010001270A (ko) 1999-06-03 2001-01-05 복성해 혈관신생을 억제하는 새로운 이소쿠마린 유도체
WO2001026648A1 (fr) 1999-10-13 2001-04-19 Senju Pharmaceutical Co., Ltd. Preparation d'adhesif a usage ophtalmique pour l'absorption par voie percutanee
AU1735001A (en) * 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
EP1334718A4 (en) * 2000-10-26 2007-07-18 Senju Pharma Co DRUG COMPOSITION CONTAINING DIPEPTIDYL ALDEHYDE COMPOUND
WO2002048096A1 (fr) * 2000-12-12 2002-06-20 Senju Pharmaceutical Co., Ltd. Derives d'hydrazone et utilisation de ceux-ci dans des medicaments
MXPA03011197A (es) 2001-06-06 2004-02-26 Lilly Co Eli Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
US7115607B2 (en) * 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
EP1489076B1 (en) * 2002-03-15 2008-08-13 Senju Pharmaceutical Co., Ltd. Cyclic hemiacetal derivative and use thereof
ATE473216T1 (de) * 2002-03-29 2010-07-15 Senju Pharma Co Hydroxymorpholinonderivat und dessen medizinische verwendung
EP1354586A1 (en) * 2002-04-20 2003-10-22 Aventis Pharma Deutschland GmbH The use of hydroxpyridone-derivatives in wound healing
DE60330038D1 (de) 2002-07-22 2009-12-24 Senju Pharma Co Neue alpha-ketoamidderivate und deren verwendung
GB0314262D0 (en) 2003-06-19 2003-07-23 Univ Nottingham Trent Novel compounds and methods of using the same
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
EP2541716A1 (en) 2010-02-25 2013-01-02 Panasonic Corporation Demand and supply control apparatus, demand and supply control method, and program
CN103052382B (zh) 2010-07-14 2014-10-22 千寿制药株式会社 α-酮酰胺衍生物的固体分散体
GB201218084D0 (en) * 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine
GB201220474D0 (en) * 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
WO2019217410A1 (en) * 2018-05-07 2019-11-14 Neuro Theranostics, Inc. Compositions and methods for treating traumatic brain injury
WO2022187491A1 (en) * 2021-03-03 2022-09-09 The Texas A& M University System Inhibitors of cysteine proteases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50137951A (no) 1974-04-27 1975-11-01
JPS5754157A (en) 1980-09-19 1982-03-31 Nippon Kayaku Co Ltd L-argininal derivative and its preparation
PT84170B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
JPH0832698B2 (ja) * 1987-05-08 1996-03-29 日本ケミファ株式会社 ピペラジン誘導体
JP2536754B2 (ja) * 1987-05-08 1996-09-18 日本ケミファ株式会社 ピペラジン誘導体
US5510531A (en) 1989-04-10 1996-04-23 Suntory Limited Proteinase inhibitor
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
EP0395309B1 (en) * 1989-04-28 1995-12-27 Takara Shuzo Co. Ltd. Human calpastatin-like polypeptide
WO1992014696A2 (en) 1991-02-22 1992-09-03 The Du Pont Merck Pharmaceutical Company SUBSTITUTED α-AMINOALDEHYDES AND DERIVATIVES
EP0504938A3 (en) * 1991-03-22 1993-04-14 Suntory Limited Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient
CA2071621C (en) * 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5607831A (en) 1993-03-25 1997-03-04 The United States Of America As Represented By The Department Of Health And Human Services In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
JP3599287B2 (ja) * 1993-04-28 2004-12-08 三菱化学株式会社 スルホンアミド誘導体
WO1996010014A1 (en) * 1994-09-27 1996-04-04 Takeda Chemical Industries, Ltd. Aldehyde derivatives as upsteine protease inhibitors
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
EP0731107A1 (en) * 1995-02-13 1996-09-11 Takeda Chemical Industries, Ltd. Production of aldehyde derivatives
CA2217850A1 (en) 1995-05-10 1996-11-14 Chirotech Technology Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
CA2226740A1 (en) * 1995-07-13 1997-01-30 Mitsuyoshi Azuma Piperazine derivative and its uses
KR100490807B1 (ko) 1995-11-28 2005-10-14 세파론, 인코포레이티드 시스테인및세린프로테아제의d-아미노산함유억제제

Also Published As

Publication number Publication date
ATE230275T1 (de) 2003-01-15
AU716495B2 (en) 2000-02-24
ES2190139T3 (es) 2003-07-16
EP0771565B1 (en) 2003-01-02
US6057290A (en) 2000-05-02
DE69625622T2 (de) 2003-08-14
HUP9602943A2 (en) 1997-08-28
EP0771565A3 (en) 1998-11-04
NO964514D0 (no) 1996-10-24
CA2188817C (en) 2010-01-26
AR004694A1 (es) 1999-03-10
BR9605267A (pt) 1998-07-21
MX9605156A (es) 1998-05-31
ATE239698T1 (de) 2003-05-15
CA2188817A1 (en) 1997-04-26
DE69625575D1 (de) 2003-02-06
PL316669A1 (en) 1997-04-28
EP0927716B1 (en) 2003-05-07
US6551999B1 (en) 2003-04-22
EP0771565A2 (en) 1997-05-07
DE69625575T2 (de) 2003-09-25
EP0927716A1 (en) 1999-07-07
ATE230389T1 (de) 2003-01-15
HUP9602943A3 (en) 1998-03-02
DE69625622D1 (de) 2003-02-06
DE69628050T2 (de) 2004-04-01
DE69628050D1 (de) 2003-06-12
AU7038496A (en) 1997-05-01
NO964514L (no) 1997-04-28

Similar Documents

Publication Publication Date Title
ES2193615T3 (es) .nhibidor de la angiogenesis.
ECSP034815A (es) "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas"
ECSP034916A (es) Oxazolidinonas substituidas para terapia de combinacion
AR038605A1 (es) Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
ECSP034732A (es) Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias
ES2174992T3 (es) Productos intermediarios para la obtencion de compuestos inhibidores de proteasas retrovirales.
AR109263A2 (es) Composición que comprende moxidectina
AR073009A1 (es) Produccion, formulacion, y usos de formulaciones de proteina de harpina liquidas estables
HN1999000088A (es) Composiciones estabilizadas
AR023388A1 (es) INHIBIDORES DE aP2 DE BIFENILOS QUE CONTIENEN COMPUESTOS HETEROCICLICOS Y METODO DE TRATAMIENTO
ES2193901T1 (es) Derivados de prostaglandina para el tratamiento de glaucoma o hipertension ocular.
MXPA04002702A (es) Forma de dosificacion para el tratamiento de diabetes mellitus.
ES2250416T3 (es) Estimulante de secreciohn de hormona de crecimiento.
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
ES2182255T3 (es) Agente de blanqueo fluorescente.
CO4960655A1 (es) Nueva composicion y su uso
ES2155517T3 (es) Derivados del acido n-acetil-neuraminico y procedimientos para su preparacion.
AR021241A1 (es) Inhibidores de proteasas
PA8542501A1 (es) Composicion
SE0004101D0 (sv) New use
ATE518533T1 (de) Pharmazeutische zusammensetzung, die einen spezifischen aminopeptidase-a inhibitor enthält, insbesondere ec33, zur senkung des blutdrucks